Enhertu Becomes a New Standard in Early-Stage Breast Cancer: Critical FDA Approval
In this article
Enhertu Is Changing Standards in Both Neoadjuvant and Adjuvant Indications
A Paradigm Shift in Early-Stage Management
HER2-positive breast cancer accounts for approximately 15-20% of all breast cancer cases and is known for its aggressive biological behavior, high proliferation index, and tendency toward early systemic spread. Although the introduction of monoclonal antibodies such as trastuzumab and pertuzumab into clinical practice dramatically improved prognosis, powerful approaches to further reduce the risk of recurrence were needed, particularly in high-risk Stage II-III locally advanced disease.
The clinical approach to managing early-stage HER2-positive breast cancer with curative intent is divided into two main periods:
CURRENT CLINICAL APPROACH AND STRATEGIES
- Neoadjuvant Phase: The primary goal is to reduce tumor burden, facilitate surgery (enable breast-conserving surgery), and, most importantly, test tumor sensitivity in vivo. The current standard clinical protocol generally consists of dual HER2 blockade accompanying a taxane combination (trastuzumab + pertuzumab; THP regimen). Achieving a pathological complete response (pCR) in the surgical specimen is the strongest predictor of long-term survival.
- Adjuvant Phase: After neoadjuvant therapy and surgery, the patient's management pathway is shaped by the pathological response. If microscopic or macroscopic viable tumor cells remain in the surgical specimen (residual invasive disease), this indicates a high risk of recurrence. Historically, the standard in this setting was ado-trastuzumab emtansine (T-DM1; Kadcyla), an emtansine-conjugated ADC.
What Is T-DXd? Next-Generation Power in Smart Bomb Technology
Trastuzumab deruxtecan (T-DXd), a next-generation antibody-drug conjugate (ADC), combines the strengths of targeted biological therapy and cytotoxic chemotherapy. The drug consists of three main components: a humanized IgG1 monoclonal antibody (trastuzumab) that targets human epidermal growth factor receptor 2 (HER2) with high affinity, a stable tetrapeptide-based linker that can be cleaved inside the tumor cell, and a highly potent cytotoxic payload consisting of a topoisomerase I inhibitor (deruxtecan / DXd).
T-DXd has two main pharmacological properties that distinguish it from conventional T-DM1 and enable it to show such high efficacy in early-stage disease: A High Drug-to-Antibody Ratio (DAR) (it carries approximately 8 cytotoxic molecules per antibody; this ratio is approximately 3.5 for T-DM1) and, thanks to its membrane-permeable active cytotoxic payload, the ability to kill neighboring cells as well, known as the bystander effect. This effect plays a critical role in overcoming HER2 heterogeneity within the tumor.
DESTINY-Breast11 Clinical Design and Results
The global, multicenter, randomized, open-label Phase 3 trial conducted in patients with high-risk, locally advanced or inflammatory HER2-positive early-stage breast cancer — DESTINY-Breast11 — provided the data on which approval of the neoadjuvant indication is based.
DESTINY-BREAST11 TRIAL DESIGN AND PROTOCOL
- Patient Population and Criteria: A total of 927 patients. High-risk patients aged ≥18 years, with an ECOG performance status of 0 or 1, adequate organ function, and left ventricular ejection fraction (LVEF) ≥50%, whose HER2 positivity was confirmed by a central laboratory.
- Randomization Arms (1:1:1):
Arm 1: 8 cycles of T-DXd monotherapy (n = 286 - *This arm was closed early following an early efficacy assessment conducted on the recommendation of the independent data monitoring committee.)
Arm 2: 4 cycles of T-DXd followed by 4 cycles of the THP combination (n = 321)
Arm 3 (Standard Care / Control): 4 cycles of dose-dense doxorubicin and cyclophosphamide followed by 4 cycles of THP (ddAC-THP; n = 320) - Primary Endpoint: Pathological Complete Response (pCR) rate.
The trial's primary results showed that patients receiving 4 cycles of T-DXd followed by 4 cycles of THP achieved a statistically and clinically significantly higher pathological complete response rate than with the standard anthracycline-containing ddAC-THP regimen:
DESTINY-Breast05: A Direct Comparison in Residual Disease
The global, multicenter, randomized, open-label Phase 3 trial enrolling high-risk patients with invasive residual disease in the breast and/or axillary lymph nodes at surgery despite receiving neoadjuvant chemotherapy and HER2-targeted therapy — DESTINY-Breast05 — delivered the strong results on which approval of the adjuvant indication is based.
Trial Conduct: Patients who were inoperable after the neoadjuvant phase, or operable but remained axillary lymph node-positive, were randomized 1:1 into two arms. The first group received a maximum of 14 cycles of T-DXd at 5.4 mg/kg every 3 weeks; the active control group received 14 cycles of T-DM1 (the historical standard of care) at 3.6 mg/kg every 3 weeks. The protocol permitted concurrent adjuvant endocrine therapy and radiotherapy in accordance with local guidelines.
In the analysis of the primary endpoint, 3-year Invasive Disease-Free Survival (iDFS), T-DXd demonstrated superiority over the previous standard, T-DM1, by halving the risk of recurrence or death:
WHAT DO THESE DATA MEAN FOR CLINICAL PRACTICE?
The DESTINY-Breast05 results have brought about a very clear paradigm shift in the group of patients with early-stage HER2-positive breast cancer who do not achieve a complete response after neoadjuvant therapy and have a high risk of recurrence. By lowering the hazard ratio (HR) to 0.47, T-DXd achieved a 53% reduction in recurrence risk and established clear superiority over T-DM1, becoming the new first-line adjuvant standard in this patient group.
Toxicity Management: Monitoring for Interstitial Lung Disease (ILD)
Although T-DXd is a highly effective molecule, it has a distinctive toxicity profile that requires clinicians to exercise extreme care in management. The drug's approved prescribing label contains very important warnings.
DOSING AND CLINICAL MONITORING PRINCIPLES
- Neoadjuvant Dosing Schedule: The recommended dose is 5.4 mg/kg intravenously every 3 weeks. In this schedule, after 4 cycles, treatment switches sequentially to 4 cycles of the THP combination (Taxane + Trastuzumab + Pertuzumab).
- Adjuvant Dosing Schedule: The recommended dose is 5.4 mg/kg intravenously every 3 weeks for a maximum of 14 cycles, provided that disease recurrence or intolerable toxicity does not develop.
- Combination With Radiotherapy and Monitoring: A mandatory ILD surveillance and follow-up program must be implemented, as required by the protocol, for patients receiving concurrent radiotherapy during adjuvant treatment. If early symptoms (cough, dyspnea, fever) are detected, the drug must be discontinued immediately and assessment with radiological imaging performed.
The Early-Stage HER2 Management Ecosystem
Within the clinical dynamics of 2026, the comparative analysis of options in the neoadjuvant and adjuvant treatment ecosystem is as follows:
DUAL HER2 BLOCKADE (THP REGIMEN)
The standard approach in the neoadjuvant phase together with taxane combinations. The pCR rate is in the 50-55% range. It requires management of cardiotoxicity and diarrhea. It is one of the cornerstones of the curative treatment framework.
T-DXd (ENHERTU) — NEW DUAL APPROVAL
In the neoadjuvant phase, it established superiority over the anthracycline-based ddAC-THP regimen by increasing pCR to 67.3%. In the adjuvant phase, it became the new standard of care for residual disease management compared with T-DM1, with an iDFS rate of 92.4%. ILD monitoring is vitally important.
T-DM1 (KADCYLA) — PREVIOUS ADJUVANT STANDARD
It had been the standard adjuvant choice since the KATHERINE trial for patients with residual invasive disease after neoadjuvant therapy. Following the direct comparison data from DESTINY-Breast05, it is giving way to T-DXd, which offers better iDFS.
ANTHRACYCLINE-CONTAINING REGIMENS (ddAC)
Anthracycline regimens historically used frequently in neoadjuvant protocols are being pushed into the background in early-stage clinical practice, particularly because T-DXd-based anthracycline-free approaches offer high pCR and a more acceptable cardiac toxicity profile.
⚡ WHY DOES IT MATTER?
Early-stage HER2-positive breast cancer is one of the groups with the highest chances of cure (complete recovery) with appropriate and aggressive treatment. Bringing T-DXd's revolutionary success in metastatic disease into the early curative setting both maximizes pathological complete response rates (pCR) before surgery and significantly increases patients' chances of complete recovery by halving recurrence risk (iDFS) in the highest-risk group with remaining tumor after surgery.
✅ STRENGTHS / EVIDENCE
Efficacy proven in two large Phase 3 trials. Superiority over standard care (ddAC-THP) with a 67.3% pCR rate in DESTINY-Breast11. A marked difference in the 3-year iDFS rate versus T-DM1 in DESTINY-Breast05 (92.4% vs 83.7%) and an impressive risk reduction ratio (HR) of 0.47. Potential to optimize systemic toxicity and the risks of late cardiotoxicity by reducing anthracycline exposure.
⚠️ LIMITATIONS AND SAFETY
A clear Boxed Warning for ILD / pneumonitis; the need for very close clinical monitoring, particularly with sequential or concurrent use alongside radiotherapy. Potential serious adverse effects such as left ventricular dysfunction (requiring LVEF monitoring) and neutropenia. Debate over whether the DESTINY-Breast11 control arm (the anthracycline-containing arm) fully reflects current clinical practice patterns. High treatment cost and global/local reimbursement barriers in early-stage use.
🩺 IMPLICATIONS FOR CLINICAL PRACTICE
In breast cancer multidisciplinary boards, anthracycline-free protocols with T-DXd followed sequentially by THP should now be discussed as a strong alternative in neoadjuvant planning for locally advanced (Stage II-III) HER2-positive patients. For patients who receive neoadjuvant therapy, undergo surgery, and have residual invasive disease in their specimen, switching from T-DM1 to T-DXd in adjuvant treatment should be accepted as the new treatment standard. In clinics, LVEF should be monitored with echocardiography every 3 months throughout treatment, and patients should be educated about pulmonary symptoms.
❓ FUTURE QUESTIONS
For patients who achieve pCR (complete response) after neoadjuvant T-DXd, will trastuzumab/pertuzumab dual blockade alone be sufficient in the adjuvant phase, or should ADC maintenance continue? Will early-stage use of T-DXd lead to the tumor developing resistance to T-DXd in the event of a possible recurrence in later years? How will long-term overall survival (OS) analyses mature in the DESTINY trials? Considering cost-effectiveness analyses, how quickly will health authorities include this high-cost molecule in first-line reimbursement for early-stage treatment regimens?
References
- U.S. Food and Drug Administration (FDA). FDA approves fam-trastuzumab deruxtecan-nxki for neoadjuvant and adjuvant treatment of HER2-positive early-stage breast cancer. May 15, 2026.
- Harbeck N, Modi S, Pusztai L, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Annals of Oncology 2026;37(suppl 2):166-179. doi:10.1016/j.annonc.2025.10.019
- Geyer CE, Park YH, Shao Z, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): interim analysis of DESTINY-Breast05. Presented at: 2025 ESMO Congress; October 17-21, 2025; Berlin, Germany. Abstract LBA1.
- Enhertu (fam-trastuzumab deruxtecan-nxki). Prescribing Information; Revised May 2026. Daiichi Sankyo, Inc. and AstraZeneca Pharmaceuticals LP.
This article has been prepared solely for medical information and literature review purposes and contains no treatment advice or direction. The early-stage indications for fam-trastuzumab deruxtecan-nxki (Enhertu) were approved by the US FDA in May 2026. The drug's licensing and reimbursement conditions in Turkey may vary. Treatment planning must strictly be carried out by a specialist medical oncologist and a multidisciplinary breast cancer board according to the patient's individual clinical data.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.